title: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
abstract: Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.
authors.affiliation: Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, UK.
authors.forename: D
authors.initials: D
authors.lastname: Papamichael
authors.forename: C J
authors.initials: CJ
authors.lastname: Gallagher
authors.forename: R T
authors.initials: RT
authors.lastname: Oliver
authors.forename: P W
authors.initials: PW
authors.lastname: Johnson
authors.forename: J
authors.initials: J
authors.lastname: Waxman
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use*; D014516:Ureteral Neoplasms / Q000188:drug therapy* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel